StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

ABUS — Arbutus Biopharma Corporation

UNDERVALUED (MOS +64.1%) · Quality 55/100

Price
5.01
Intrinsic value
13.96
Margin of safety
+64.1%
Implied growth (reverse DCF)
-
a described calculation from stated inputs, not a forecast
Value Score
38.4
Quality
55
Psychology
-5.3
Discovery
22.1
price/volume attention only
Moat score
16
erosion: none

Value Score: top 40% of Russell 3000 · Quality: top 46%

Open the interactive Deep Dive for ABUS →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/ABUS - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is ABUS undervalued?

As of 2026-09-19, ABUS trades at 5.01 against a computed intrinsic value of 13.96 (+64.1% margin of safety) - StocksDeepDive's valuation label for this is UNDERVALUED. This is a described calculation from public data, not a recommendation.

What is Arbutus Biopharma Corporation's Value Score?

Arbutus Biopharma Corporation's Value Score is 38.4 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.